Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2024-03-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团十届二十二次监事会决议
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of Kunming Pharmaceutical Corporation regarding various reports and proposals related to the 2023 fiscal year. It mentions the supervisory board's approval of the 2023 Supervisory Board Work Report, Internal Control Evaluation Report, Internal Control Audit Report, Annual Report and its summary, ESG Report, Financial Final Accounts Report, Profit Distribution Plan, Fund Usage Report, Asset Impairment Provision, and Annual Remuneration Proposal. The document states that these reports are published in full on the Shanghai Stock Exchange website and that the resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full reports but is an official announcement of the supervisory board's resolutions and approvals related to the annual reports and other documents. The document length is short (1864 characters) and it references full reports published elsewhere. Therefore, this document is an announcement of supervisory board resolutions related to the annual report and other related reports, not the annual report itself. This fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement of supervisory board decisions and approvals, not the full annual report or financial statements.
2024-03-21 Chinese
昆药集团董事会审计与风险控制委员会对会计师事务所2023年度履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit and Risk Control Committee regarding the supervision of the accounting firm KPMG Huazhen for the fiscal year 2023. It details the appointment process, the audit work performed by the accounting firm, the committee's oversight activities, and an overall evaluation of the audit firm's performance. The document does not contain the full annual report or financial statements but focuses on the audit supervision and the audit firm's qualifications and work. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and related supervisory information. The document length is 2399 characters, which is relatively short but contains substantive content about the audit process and oversight, not merely an announcement or certification. Therefore, it should be classified as AR rather than a report publication announcement or regulatory filing.
2024-03-21 Chinese
昆药集团2023年独立董事述职报告（杨智）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2023" for Kunming Pharmaceutical Corporation. It details the independent director's duties, attendance at board and shareholder meetings, opinions on related party transactions, external guarantees, use of raised funds, remuneration, stock incentive plans, appointment of auditors, accounting policy changes, dividend distribution, asset impairment provisions, information disclosure, and internal control execution during the year 2023. The content is a detailed report on the independent director's annual duties and opinions related to corporate governance and financial matters. It is not a full annual report (10-K), nor an audit report, nor a simple announcement. It is a management/governance related report focusing on the independent director's role and activities over the year. This fits best under Board/Management Information (MANG) as it relates to board member duties and governance activities. The document length (8923 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2024-03-21 Chinese
昆药集团关于2023年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Corporation regarding its 2023 annual profit distribution plan. It details the dividend per share, total dividend amount, and the decision-making process including board and supervisory opinions. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related procedural information. It is a formal announcement about the dividend plan, not the full annual report or earnings release. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is short (1835 characters), consistent with a dividend announcement rather than a full report.
2024-03-21 Chinese
昆药集团2023年独立董事述职报告（刘珂）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2023" for Kunming Pharmaceutical Corporation. It details the independent director's duties, attendance at board and shareholder meetings, opinions on related party transactions, external guarantees, use of raised funds, stock incentive plans, appointment of auditors, accounting policy changes, dividend distribution, asset impairment provisions, information disclosure, and internal control execution. The content is a detailed report on the independent director's annual work and opinions on governance and financial matters for the year 2023. It is not a full annual report, audit report, or earnings release, but a specific governance-related report by an independent director. This fits best under Board/Management Information (MANG), which includes announcements or reports related to board members and their activities. The document length (8337 characters) and detailed content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2024-03-21 Chinese
关于昆药集团2023年度非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2024-03-21 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.